Toxicogenomics - A novel opportunity to probe lupus susceptibility and pathogenesis

International Immunopharmacology

Volumn 8, Issue 10, 2008, Pages 1330-1337

  Tsay, Gregory J ^a   Zouali, Moncef ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b INSERM   (France)

Author keywords

Autoimmunity; Lupus; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ACEBUTOLOL; CAPTOPRIL; CARBAMAZEPINE; CHLORPROMAZINE; HYDRALAZINE; ISONIAZID; METHYLDOPA; PENICILLAMINE; PHENYTOIN; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; SULFONAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFECTION RISK; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

B-LYMPHOCYTES; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL POLLUTANTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACEUTICAL PREPARATIONS; TOXICOGENETICS;

EID: 50949113545     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.03.010     Document Type: Article

References (58)

1. Zouali M. Taming lupus. Sci Am 292 3 (Mar 2005) 58-65
2. Tsay G.J., and Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol 72 11 (Nov 30 2006) 1453-1459
3. Uetrecht J.P. Current trends in drug-induced autoimmunity. Toxicology 119 1 (Apr 11 1997) 37-43
4. Rubin R.L. Drug-induced lupus. Toxicology 209 2 (Apr 15 2005) 135-147
5. Smit A.J., Meijer S., Wesseling H., Donker A.J., and Reitsma W.D. The effects of alpha-adrenoceptor blockade on dopamine-induced renal vasodilation and natriuresis. Naunyn Schmiedebergs Arch Pharmacol 343 2 (Feb 1991) 143-148
6. Tournade H., Pelletier L., Pasquier R., Vial M.C., Mandet C., and Druet P. D-penicillamine-induced autoimmunity in Brown-Norway rats. Similarities with HgCl2-induced autoimmunity. J Immunol 144 8 (Apr 15 1990) 2985-2991
7. Aucoin D.P., Peterson M.E., Hurvitz A.I., Drayer D.E., Lahita R.G., Quimby F.W., et al. Propylthiouracil-induced immune-mediated disease in the cat. J Pharmacol Exp Ther 234 1 (Jul 1985) 13-18
8. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140 7 (Apr 1 1988) 2197-2200
9. Yung R.L., Quddus J., Chrisp C.E., Johnson K.J., and Richardson B.C. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154 6 (Mar 15 1995) 3025-3035
10. Mazari L., Ouarzane M., and Zouali M. Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 104 15 (Apr 10 2007) 6317-6322
11. Cannat A., and Seligmann M. Induction by isoniazid and hydrallazine of antinuclear factors in mice. Clin Exp Immunol 3 1 (Jan 1968) 99-105
12. ten Veen J.H., and Feltkamp T.E. Studies on drug induced lupus erythematosus in mice. I. Drug induced antinuclear antibodies (ANA). Clin Exp Immunol 11 2 (Jun 1972) 265-276
13. ten Veen J.H. Studies on drug-induced lupus erythematosus in mice. II. Drug-induced smooth muscle and skeletal muscle antibodies. Clin Exp Immunol 15 3 (Nov 1973) 375-384
14. Mongey A.B., Sim E., Risch A., and Hess E. Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide. J Rheumatol 26 8 (Aug 1999) 1721-1726
15. Speirs C., Fielder A.H., Chapel H., Davey N.J., and Batchelor J.R. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1 8644 (Apr 29 1989) 922-924
16. Totoritis M.C., Tan E.M., McNally E.M., and Rubin R.L. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 318 22 (Jun 2 1988) 1431-1436
17. Viau M., and Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114 1 (Jan 2005) 17-26
18. Zouali M., and Sarmay G. B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum 50 9 (Sep 2004) 2730-2741
19. Hasler P., and Zouali M. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin Ther Targets 10 6 (Dec 2006) 803-815
20. Ouarzane M., and Zouali M. Novel opportunities for therapeutic targeting in systemic autoimmune diseases. Methods Mol Biol 361 (2007) 285-297
21. Zouali M. Receptor editing and receptor revision in rheumatic autoimmune diseases. Trends Immunol 29 3 (Mar 2008) 103-109
22. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., and Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 18 4 (Apr 1991) 530-534
23. Watson R.E., and Goodman J.I. Epigenetics and DNA methylation come of age in toxicology. Toxicol Sci 67 1 (May 2002) 11-16
24. Huck S., and Zouali M. DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Clin Immunol Immunopathol 80 1 (Jul 1996) 1-8
25. Huck S., Deveaud E., Namane A., and Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J 13 11 (Aug 1999) 1415-1422
26. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 112-113 (Mar 15 2000) 421-432
27. Hess E.V. Environmental chemicals and autoimmune disease: cause and effect. Toxicology 181-182 (Dec 27 2002) 65-70
28. Klareskog L., Padyukov L., and Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 19 1 (Jan 2007) 49-54
29. Peeva E., and Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 101 2 (Nov 15 2005) 123-143
30. Stevens J.L., Liu H., Halleck M., Bowes R.C., Chen Q.M., and van de Water B. Linking gene expression to mechanisms of toxicity. Toxicol Lett 112-113 (Mar 15 2000) 479-486
31. Goldstein D.B., Tate S.K., and Sisodiya S.M. Pharmacogenetics goes genomic. Nat Rev Genet 4 12 (Dec 2003) 937-947
32. Tate S.K., and Goldstein D.B. Will tomorrow's medicines work for everyone?. Nat Genet 36 11 Suppl (Nov 2004) S34-S42
33. Waring J.F., Ciurlionis R., Jolly R.A., Heindel M., and Ulrich R.G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 120 1-3 (Mar 31 2001) 359-368
34. de Longueville F., Atienzar F.A., Marcq L., Dufrane S., Evrard S., Wouters L., et al. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol Sci 75 2 (Oct 2003) 378-392
35. Huang Q., Jin X., Gaillard E.T., Knight B.L., Pack F.D., Stoltz J.H., et al. Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat Res 549 1-2 (May 18 2004) 147-167
36. Rus V., Atamas S.P., Shustova V., Luzina I.G., Selaru F., Magder L.S., et al. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 102 3 (Mar 2002) 283-290
37. Maas K., Chan S., Parker J., Slater A., Moore J., Olsen N., et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 169 1 (Jul 1 2002) 5-9
38. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100 5 (Mar 4 2003) 2610-2615
39. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 6 (Mar 17 2003) 711-723
40. Crow M.K., and Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 5 6 (2003) 279-287
41. Pereira E., Tamia-Ferreira M.C., Cardoso R.S., Mello S.S., Sakamoto-Hojo E.T., Passos G.A., et al. Immunosuppressive therapy modulates T lymphocyte gene expression in patients with systemic lupus erythematosus. Immunology 113 1 (Sep 2004) 99-105
42. Alcorta D.A., Barnes D.A., Dooley M.A., Sullivan P., Jonas B., Liu Y., et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 72 7 (Oct 2007) 853-864
43. Peterson K.S., Huang J.F., Zhu J., D'Agati V., Liu X., Miller N., et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 113 12 (Jun 2004) 1722-1733
44. Liu J., Karypis G., Hippen K.L., Vegoe A.L., Ruiz P., Gilkeson G.S., et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 7 2 (Mar 2006) 156-168
45. Teramoto K., Negoro N., Kitamoto K., Iwai T., Iwao H., Okamura M., et al. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci 106 1 (Jan 2008) 56-67
46. Zhong S., Huang M., Yang X., Liang L., Wang Y., Romkes M., et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 62 4 (Oct 2006) 457-472
47. Takada K., Arefayene M., Desta Z., Yarboro C.H., Boumpas D.T., Balow J.E., et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50 7 (Jul 2004) 2202-2210
48. Singh G., Saxena N., Aggarwal A., and Misra R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 34 4 (Apr 2007) 731-733
49. Gunnarsson I., Kanerud L., Pettersson E., Lundberg I., Lindblad S., and Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36 10 (Oct 1997) 1089-1094
50. Soejima M., Sugiura T., Kawaguchi Y., Kawamoto M., Katsumata Y., Takagi K., et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9 2 (2007) R23
51. Rychlik-Sych M., Skretkowicz J., Gawronska-Szklarz B., Gornik W., Sysa-Jedrzejowska A., and Skretkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 58 1 (Jan-Feb 2006) 22-29
52. Vazgiourakis V., Sidiropoulos P., Bertsias G., Koutsounaki E., Fragouli E., Raptopoulou A., et al. Association of the nitric oxide synthase (eNOS) gene polymorphism with increased risk for both lupus glomerulonephritis and rheumatoid arthritis in a single genetically homogeneous population. Lupus 16 11 (2007) 867-874
53. Parsa A., Peden E., Lum R.F., Seligman V.A., Olson J.L., Li H., et al. Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families. Genes Immun 3 Suppl 1 (Oct 2002) S42-S46
54. Xu J., Wang Y., Pan F., Stankovich J., Ye D., Lian L., et al. Association of ACE gene polymorphism with genetic susceptibility to systemic lupus erythematosus in a Chinese population: a family-based association study. J Rheumatol 34 12 (Dec 2007) 2408-2411
55. Saeed M., Mekan S.F., Rabbani M.A., Arain F.M., Arif M., and Shaharyar S. Angiotensin converting enzyme (ACE) gene polymorphisms and lupus disease severity: a promising link. Ann Rheum Dis 64 1 (Jan 2005) 164-165
56. Douglas G., Reilly C., Dooley M.A., Page G., Cooper G., and Gilkeson G. Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. J Rheumatol 31 9 (Sep 2004) 1756-1762
57. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., and Song G.G. Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis. J Rheumatol 33 4 (Apr 2006) 698-702
58. Shaffer A.L., Rosenwald A., Hurt E.M., Giltnane J.M., Lam L.T., Pickeral O.K., et al. Signatures of the immune response. Immunity 15 3 (Sep 2001) 375-385